Lipoglycopeptide

Results: 8



#Item
1Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, [removed]Theravance, Inc., and Astellas Pharma Inc. announced t

Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, [removed]Theravance, Inc., and Astellas Pharma Inc. announced t

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-18 21:56:16
2Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-10-28 20:07:57
3Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/July 18, [removed]Theravance, Inc. (NASDAQ: THRX), and Astellas

Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/July 18, [removed]Theravance, Inc. (NASDAQ: THRX), and Astellas

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-19 00:50:37
4FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting

FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting

Add to Reading List

Source URL: www.fda.gov

Language: English
5Dalbavancin for Injection Anti-Infective Drugs Advisory Committee Durata Therapeutics International B.V. NDA[removed]

Dalbavancin for Injection Anti-Infective Drugs Advisory Committee Durata Therapeutics International B.V. NDA[removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
6Introductory Remarks - Anti-Infective Drugs Advisory Committee Meeting for Dalbavancin March 31, 2014 John Alexander, MD, MPH Medical Team Leader, DAIP

Introductory Remarks - Anti-Infective Drugs Advisory Committee Meeting for Dalbavancin March 31, 2014 John Alexander, MD, MPH Medical Team Leader, DAIP

Add to Reading List

Source URL: www.fda.gov

Language: English
7Initial approval[removed]Most recent modification[removed]NDA[removed]and NDA[removed]VIBATIV (telavancin) for injection [Lipoglycopeptide]

Initial approval[removed]Most recent modification[removed]NDA[removed]and NDA[removed]VIBATIV (telavancin) for injection [Lipoglycopeptide]

Add to Reading List

Source URL: www.fda.gov

Language: English
8Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization

Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization

Add to Reading List

Source URL: www.farm.ucl.ac.be

Language: English - Date: 2009-10-27 07:38:44